Free tool
FAERS Monitor: Estrogel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021166 or its brand name (Estrogel, Estradiol). Reports on generic versions are filed under their own applications.
Reports
48,633
Serious
23,773
49% of reports
Hospitalization
7,526
Death reported
927
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,071
- headache3,072
- fatigue3,055
- nausea3,045
- off label use2,580
- pain2,197
- diarrhoea2,068
- dizziness1,807
- arthralgia1,787
- breast cancer female1,713
- dyspnoea1,640
- pruritus1,619
- rash1,606
- product adhesion issue1,539
- insomnia1,430
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 527 |
| 2005 | 591 |
| 2006 | 411 |
| 2007 | 1,475 |
| 2008 | 446 |
| 2009 | 610 |
| 2010 | 972 |
| 2011 | 861 |
| 2012 | 1,173 |
| 2013 | 923 |
| 2014 | 1,144 |
| 2015 | 1,987 |
| 2016 | 2,435 |
| 2017 | 2,227 |
| 2018 | 2,589 |
| 2019 | 3,069 |
| 2020 | 3,111 |
| 2021 | 2,938 |
| 2022 | 3,162 |
| 2023 | 3,675 |
| 2024 | 3,849 |
| 2025 | 5,325 |
| 2026 | 5,132 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,005,526 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,713 | 29.6 | 28.2 | 44,276 |
| product adhesion issueSignal | 1,539 | 19.4 | 18.5 | 25,759 |
| insomniaSignal | 1,430 | 2.3 | 2.2 | 1,091 |
| headacheSignal | 3,072 | 2.1 | 2.1 | 1,874 |
| arthralgia | 1,787 | 1.9 | 1.8 | 724 |
| pruritus | 1,619 | 1.8 | 1.7 | 612 |
| fatigue | 3,055 | 1.7 | 1.6 | 910 |
| nausea | 3,045 | 1.7 | 1.6 | 839 |
| rash | 1,606 | 1.6 | 1.5 | 363 |
| dizziness | 1,807 | 1.6 | 1.5 | 380 |
| pain | 2,197 | 1.5 | 1.5 | 438 |
| diarrhoea | 2,068 | 1.4 | 1.3 | 229 |
| drug ineffective | 4,071 | 1.3 | 1.3 | 367 |
| off label use | 2,580 | 1.3 | 1.2 | 159 |
| dyspnoea | 1,640 | 1.3 | 1.2 | 86 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.